Advisory panel supports ending lifetime MSM deferral policy | Read AABB's joint statement on the recommendation to change MSM deferral policy | Scientists discover stem cells are responsible for lung-tissue regeneration
Web Version
November 14, 2014
AABB SmartBrief
News for the transfusion medicine and cellular therapy community

Top StorySponsored By
Advisory panel supports ending lifetime MSM deferral policy
The Advisory Committee on Blood and Tissue Safety and Availability has recommended that the Department of Health and Human Services change its lifetime deferral policy for blood donations by men who have sex with men to a one-year deferral. The FDA will make the final decision. The Hill (11/13), U.S. News & World Report (11/14), (11/14)
Share: LinkedInTwitterFacebookGoogle+Email
Quotient adds a 2-cell screen to its growing portfolio
Quotient now offers a 2-cell antibody screen for institutions that frequently test pediatric and other small volume samples. Our 2-cell screen has been carefully chosen to maximize homozygosity and optimize detection of blood group antibodies. Call your Quotient Account Executive to add this new product, so you can better address key patient segments.
Science & Health
Scientists discover stem cells are responsible for lung-tissue regeneration
A study in the journal Nature sheds light on the mechanism behind lung regeneration with the discovery of adult lung stem cells p63+/Krt5+ in distal airways of mice infected with the H1N1 virus. Jackson Laboratory researchers found that when grown in culture, the cells form alveolar-like structures and migrate to inflammation sites following infection. When the cells were removed, the subjects failed to recover from infection, which caused scarring and impaired oxygen exchange. Genetic Engineering & Biotechnology News (11/13)
Share: LinkedInTwitterFacebookGoogle+Email
Kidney patients with low hemoglobin levels at greater risk of bleeding
Patients with chronic kidney disease who have severe anemia are at greater risk for prolonged bleeding, according to a study presented at the Kidney Week meeting in Philadelphia. Hemoglobin levels below 8 mg/dL were associated with an 82% increased risk compared with Hb levels of 10 mg/dL or greater. The findings were based on data involving 1,022 patients in South Korea. Renal and Urology News (11/13)
Share: LinkedInTwitterFacebookGoogle+Email
Nanodroplets aid detection of bacteria in blood samples, researchers find
Scientists at the University of California, Irvine, have found that their Integrated Comprehensive Droplet Digital Detection technology can rapidly detect bacteria in the blood without the need for cell cultures. The test makes it easier to find bacterial markers of disease by turning blood samples into billions of small droplets. Orange County Business Journal (Irvine, Calif.) (11/13)
Share: LinkedInTwitterFacebookGoogle+Email
High serum ferritin increases mortality risk in hemodialysis patients
A study presented at the Kidney Week meeting in Philadelphia found that high serum levels of ferritin were associated with greater mortality risk in hemodialysis patients. In the study of 162,818 patients receiving thrice-weekly hemodialysis, patients with high levels of ferritin were 24% more likely to die of any cause and of causes related to infection, as well as 10% more likely to die of cardiovascular causes. Renal and Urology News (11/13)
Share: LinkedInTwitterFacebookGoogle+Email
AABB Patient Blood Management Consulting
As the paradigm of blood utilization shifts toward the evidence-based, multidisciplinary practice of patient blood management (PBM), it's imperative for your facility to implement a successful and scalable PBM program. Connect with AABB consultants who can help you identify the steps necessary for implementing a winning program, reduce unnecessary transfusions and establish PBM-specific performance measures.
Emerging Trends
Israeli wound-healing serum in Phase III trials
Israeli company Macrocure says its serum containing hyperactivated immune cells has been able to reduce diabetic foot ulcers and other wounds by 90%. Treatment involves three injections a month to the wound site. CureXcell, which is approved in Israel, is being tested in two Phase III clinical trials, and the company hopes to gain FDA approval. (11/12)
Share: LinkedInTwitterFacebookGoogle+Email
Industry News & Practice
Glaxo applies for expanded indication of eltrombopag in Europe
GlaxoSmithKline has filed an application to the European Medicines Agency for the expanded indication of Revolade, or eltrombopag, to include adults with severe aplastic anemia who have had a poor response to immunosuppressive therapy. The submission is bolstered by results of three Phase II trials supported by the National Institutes of Health. Pharmaceutical Business Review Online (11/13)
Share: LinkedInTwitterFacebookGoogle+Email
AstraZeneca to begin clinical studies of clotting antidote for Brilinta
AstraZeneca has announced that it is launching trials that will evaluate the ability of the experimental antibody MEDI2452 to reverse the blood thinning effects of Brilinta during emergencies. MEDI2452 was developed by AstraZeneca's MedImmune unit. The Telegraph (London) (tiered subscription model) (11/13), Reuters (11/13)
Share: LinkedInTwitterFacebookGoogle+Email
Doctors Without Borders to begin trials of experimental Ebola therapies
Three clinical trials will be conducted in December in Guinea and Liberia, Doctors Without Borders has announced. The trials will involve three potential Ebola treatments: brincidofovir from Chimerix, favipiravir from Fujifilm and blood plasma from Ebola survivors. The lead research teams are from the University of Oxford, the Institute of Tropical Medicine in Antwerp and the French National Institute of Health and Medical Research. Reuters (11/13), HealthDay News (11/13)
Share: LinkedInTwitterFacebookGoogle+Email
Government & Regulatory
BioCardia receives approval for late-stage trial of cell therapy for heart failure
The FDA has approved BioCardia's application to begin a late-stage study of its bone marrow-derived CardiAMP Therapy as a treatment for heart failure. The trial will involve 250 patients at as many as 40 centers. A biomarker panel will be used to identify potential participants with potent bone marrow cells. FDAnews (11/14)
Share: LinkedInTwitterFacebookGoogle+Email
Association News
New members elected to CT Section Coordinating Committee
The AABB Cellular Therapy Section has announced the results of the coordinating committee election that took place at the section's annual business meeting in Philadelphia. To see the committee membership and for additional information, visit the CT Section Coordinating Committee Web page. In addition, an article about the meeting, "The Year of the Cell-Fie: CT Section Holds Its Annual Business Meeting," is available on the AABB Annual Meeting News page.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
IRL / Molecular Med Tech IIISan Diego Blood BankSan Diego, CA
Facility processing DirectorTexas Stem CellHouston, TX
Laboratory quality manager/QC unitTexas Stem CellHouston, TX
Clinical Laboratory ScientistEisenhower Medical CenterRancho Mirage, CA
Medical Blood Bank Technologists & Sr TechnologistsUniversity of Miami Miller School of MedicineMiami, FL
Deputy Director, Regulatory AffairsAABBBethesda, MD
Click here to view more job listings.
In helping others, we shall help ourselves, for whatever good we give out completes the circle and comes back to us."
-- Flora Edwards,
American author
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tom Parks
Managing Editor:  Amanda Horn
Advertising Manager:  Annette Bacchus
  M: 240.333.6604

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information